1146159-97-8

Basic information

• Product Name: (S)-tert-butyl 3-(2-(2-hydroxyphenyl)pyrimidin-4-ylamino)pyrrolidine-1-carboxylate
• Synonyms: (S)-tert-butyl 3-(2-(2-hydroxyphenyl)pyrimidin-4-ylamino)pyrrolidine-1-carboxylate
• CAS NO: 1146159-97-8
• Molecular Weight: 356.425
• Mol File: 1146159-97-8.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: (S)-tert-butyl 3-(2-(2-hydroxyphenyl)pyrimidin-4-ylamino)pyrrolidine-1-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-tert-butyl 3-(2-(2-hydroxyphenyl)pyrimidin-4-ylamino)pyrrolidine-1-carboxylate(1146159-97-8)
• EPA Substance Registry System: (S)-tert-butyl 3-(2-(2-hydroxyphenyl)pyrimidin-4-ylamino)pyrrolidine-1-carboxylate(1146159-97-8)

Safety Data

• Hazardous Substances Data: 1146159-97-8(Hazardous Substances Data)

Upstream product

• 1146159-96-7 (S)-tert-butyl 3-(2-chloropyrimidin-4-ylamino)pyrrolidine-1-carboxylate 
• 89466-08-0 2-hydroxyphenyl boronic acid 

Downstream Products

• 1146159-99-0 (S)-2-(4-(pyrrolidin-3-ylamino)pyrimidin-2-yl)phenol 

Relevant articles and documents

THERAPEUTIC OXY-PHENYL-ARYL COMPOUNDS AND THEIR USE

The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain oxy phenyl aryl compounds (referred to herein as OPA compounds), as described herein, which, inter alia, inhibit Checkpoint Kinase 2 (CHK2) kinase function. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit CHK2 kinase function, and in the treatment of diseases and conditions that are mediated by CHK2, that are ameliorated by the inhibition of CHK2 kinase function, etc., including proliferative conditions such as cancer, etc., optionally in combination with another agent, for example, (a) a DNA topoisomerase I or II inhibitor; (b) a DNA damaging agent; (c) an antimetabolite or TS inhibitor; (d) a microtubule targeted agent; and (e) ionising radiation.